Douglas CDMO Capabilities Update April 2026: Small Molecule Drug Product

Douglas CDMO assists pharmaceutical and biotechnology companies with their contract manufacturing and development needs, specializing in high-potency softgels and liquids. They have deep experience producing prescription drugs for classifications including oncology, dermatology, the central nervous system and immunity. As one of the primary suppliers of pharmaceutical softgels to the United States and European markets, Douglas CDMO provides approximately a third of the available softgels. Alongside a commitment to delivering high quality products, the organization prioritizes excellent service, aiming to be a preferred CDMO partner for ease of doing business, responsiveness and problem-solving.

With a legacy of innovation spanning decades, Douglas CDMO was founded in 1967 by Sir Graeme Douglas and remains a privately owned business. Today, they distribute products to over 40 countries worldwide. As New Zealand’s largest pharmaceutical company, Douglas CDMO represents a world-class team of scientists, researchers, clinicians, and professionals dedicated to improving lives.